A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies

BACKGROUND: The kinase activity of mTOR involves 2 multiprotein complexes, (mTORC1-mTORC2). Targeting mTORC1 with rapalogues induces compensatory feedback loops resulting in AKT/ERK activation, which may be abrogated by mTORC2 inhibition. A first-in-human trial evaluating tolerability, pharmacokinet...

Descripción completa

Detalles Bibliográficos
Autores principales: Mateo, Joaquin, Olmos, David, Dumez, Herlinde, Poondru, Srinivasu, Samberg, Nancy L, Barr, Sharon, Van Tornout, Jan M, Jie, Fei, Sandhu, Shahneen, Tan, Daniel S, Moreno, Victor, LoRusso, Patricia M, Kaye, Stan B, Schöffski, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984800/
https://www.ncbi.nlm.nih.gov/pubmed/27002938
http://dx.doi.org/10.1038/bjc.2016.59

Ejemplares similares

Ejemplares similares